← All trials
NCT06177041
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2023
- Primary completion
- Jan 11, 2027
- Completion date
- Apr 11, 2027
- First posted
- Dec 20, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 486
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- FutureGen Biopharmaceutical (Beijing) Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.